Phil Mitchell

Cooley advised Ionis Pharmaceuticals (Nasdaq: IONS), a biotechnology research company inventing medicines that bring better futures to people with serious diseases, on its $500.3 million underwritten public offering of common stock.

Cooley advised GeBBS Healthcare Solutions, a global provider of healthcare outsourcing solutions, and ChrysCapital, a top India-focused private equity firm, on the agreement for BPEA Private Equity Fund VIII (EQT Private Capital Asia) to acquire a controlling beneficial interest in GeBBS from ChrysCapital.

Cooley advised Blue Owl Capital (NYSE: OWL), a top asset manager that is redefining alternatives, and HealthCare Royalty (HCRx), a top royalty acquisition company focused on commercial or near-commercial biopharmaceutical products, on a $250 million term loan facility with TG Therapeutics (NASDAQ: TGTX), a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases.

Cooley advised Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets, on its sale to Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, for up to $1.3 billion.

Cooley advised Talkiatry, a top provider of high-quality, in-network psychiatric care, on its $130 million equity and debt financing round.